Monotherapy with PI3K/mTOR dual inhibitors is of interest in tumor types with a particularly high incidence of aberrant PI3K pathway activation by PIK3CA mutations, amplification, or loss of PTEN tumor suppressor protein [13]. This evidence concerns the gene MTOR and neoplasm.